1. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. Issue 4 (22nd July 2019) Authors: Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine; Michielin, Francesca; James, Ian; Ceppi, Maurizio; Hasmann, Max; We... Journal: ESMO open Issue: Volume 4:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. (July 2018) Authors: Jacob, Wolfgang; James, Ian; Hasmann, Max; Weisser, Martin Journal: Cancer treatment reviews Issue: Volume 68(2018) Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab. Issue 3 (20th February 2013) Authors: Mamidi, Srinivas; Cinci, Marc; Hasmann, Max; Fehring, Volker; Kirschfink, Michael Journal: Molecular oncology Issue: Volume 7:Issue 3(2013) Page Start: 580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗